Dr. Dalia Moawad, MD, Executive Director & Disease Area Lead for Neurological Rare Diseases at Genentech discusses the three things her team learned during the pandemic from the launching of Evrysdi (risdiplam) the first at-home oral medicine for adults and children two months of age and older with spinal muscular atrophy (SMA).
Dalia Moawad, M.D. Executive Director, Head of Neurological Rare Diseases, Medical Affairs.
Dalia oversees the neurological rare disease portfolio for Genentech. At Genentech she has lead a portfolio of 10 established products, including most recently for the Evrysdi and the launch of the first influenza antiviral to come to market in 18 years. Between 2011 and 2014, she held several positions in early development and global clinical research with Bristol Myers Squibb and FivePrime Therapeutics. She spent 3 years at UCSF Gastroenterology Division focused on hepatology research before joining Genentech in 2006 with the anti-CD20 programs in immunology, first in late stage clinical development then medical affairs. Dalia holds an MBBCh from School of Medicine, Ain Shams University in Cairo.